Drug intelligence / Profile preview

LSI-401

Development stage: Preclinical
Lead developer: LipoSeuticals
Modality: Small Molecules
Administration: Intravenous

Overview

LSI-401 is a small molecule coronary vasodilator being developed by LipoSeuticals as a reformulation of regadenoson (brand name Lexiscan). It is intended for use in radionuclide myocardial perfusion imaging (MPI) to induce pharmacological stress in patients who are unable to undergo adequate exercise stress testing. As a selective agonist of the A2A adenosine receptor, LSI-401 works by increasing coronary blood flow to facilitate the detection of coronary artery disease. The reformulation likely utilizes LipoSeuticals' proprietary delivery technologies to optimize the pharmacokinetic profile or safety of the intravenous administration.

Other names: regadenoson reformulation

Targets

ADORA2A (Adenosine A₂A Receptor)

Beyond the preview

Go deeper on LSI-401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LSI-401.

Explore the full profile